Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

cyclopia sequence 8 Neoplasms, Plasma Cell 2 Multiple Myeloma 2 Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Peripheral Nervous System Diseases 1 Pancreatic Neoplasms 1 Pain 1 Oropharyngeal Neoplasms 1 Neoplasm Metastasis 1 Hypesthesia 1 Head and Neck Neoplasms 1 Exanthema 1 Esophageal Neoplasms 1 Depression 1 Colorectal Neoplasms 1 Anxiety Disorders 1 Acute Pain 1

Interventions

Fulvestrant 2 ruxolitinib 1 ceterizine hydrochloride 1 capivasertib 1 benralizumab 1 Triamcinolone Acetonide 1 Tetracycline 1 Sirolimus 1 Prednisone 1 Panitumumab 1 Minocycline 1 Loperamide 1 Irinotecan 1 IFL protocol 1 Hydrocortisone 1 Gels 1 Erlotinib Hydrochloride 1 Doxycycline 1 Dapsone 1 Clindamycin 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Exanthema × Minocycline × Clear all

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡